James Shin
Stock Analyst at Deutsche Bank
(2.55)
# 2,977
Out of 4,994 analysts
83
Total ratings
51.4%
Success rate
2.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Shin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterated: Buy | $1,285 | $1,170.14 | +9.82% | 20 | May 7, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $40 | $15.87 | +152.05% | 1 | Apr 24, 2026 | |
| STRO Sutro Biopharma | Reiterated: Buy | $51 → $55 | $16.13 | +240.98% | 4 | Mar 25, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $60 | $18.64 | +221.89% | 3 | Mar 9, 2026 | |
| MRK Merck & Co. | Upgraded: Buy | $111 → $150 | $150.91 | -0.60% | 9 | Feb 13, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $180 → $204 | $265.21 | n/a | 7 | Sep 15, 2025 | |
| GILD Gilead Sciences | Reiterated: Buy | $120 → $135 | $152.67 | n/a | 5 | Aug 11, 2025 | |
| IMTX Immatics | Initiated Coverage: Buy | $10 | $8.87 | n/a | 1 | May 28, 2025 | |
| IMCR Immunocore Holdings | Initiated Coverage: Buy | $65 | $32.42 | n/a | 1 | May 27, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $45 → $53 | $62.25 | n/a | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $305 | $410.24 | n/a | 5 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $60 → $61 | $126.93 | n/a | 5 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €27.00 | €13.11 | n/a | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.03 | n/a | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $880 → $870 | $803.90 | n/a | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 → $45 | $1.27 | n/a | 2 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $27.57 | n/a | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $10.64 | n/a | 1 | Mar 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.0001 | n/a | 1 | Dec 12, 2022 |
Eli Lilly and Company
May 7, 2026
Reiterated: Buy
Price Target: $1,285
Current: $1,170.14
Upside: +9.82%
Ascentage Pharma Group International
Apr 24, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $15.87
Upside: +152.05%
Sutro Biopharma
Mar 25, 2026
Reiterated: Buy
Price Target: $51 → $55
Current: $16.13
Upside: +240.98%
Legend Biotech
Mar 9, 2026
Reiterated: Buy
Price Target: $60
Current: $18.64
Upside: +221.89%
Merck & Co.
Feb 13, 2026
Upgraded: Buy
Price Target: $111 → $150
Current: $150.91
Upside: -0.60%
AbbVie
Sep 15, 2025
Reiterated: Hold
Price Target: $180 → $204
Current: $265.21
Upside: n/a
Gilead Sciences
Aug 11, 2025
Reiterated: Buy
Price Target: $120 → $135
Current: $152.67
Upside: n/a
Immatics
May 28, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $8.87
Upside: n/a
Immunocore Holdings
May 27, 2025
Initiated Coverage: Buy
Price Target: $65
Current: $32.42
Upside: n/a
Bristol-Myers Squibb Company
Feb 10, 2025
Reiterated: Hold
Price Target: $45 → $53
Current: $62.25
Upside: n/a
Nov 26, 2024
Reiterated: Hold
Price Target: $305
Current: $410.24
Upside: n/a
Sep 19, 2024
Reiterated: Hold
Price Target: $60 → $61
Current: $126.93
Upside: n/a
Aug 12, 2024
Reiterated: Buy
Price Target: €27.00
Current: €13.11
Upside: n/a
Aug 9, 2024
Reiterated: Buy
Price Target: $10
Current: $2.03
Upside: n/a
Aug 1, 2024
Rated: Hold
Price Target: $880 → $870
Current: $803.90
Upside: n/a
Mar 8, 2023
Reiterated: Buy
Price Target: $3 → $45
Current: $1.27
Upside: n/a
Mar 8, 2023
Reiterated: Buy
Price Target: $12
Current: $27.57
Upside: n/a
Mar 5, 2023
Reiterated: Hold
Price Target: $11
Current: $10.64
Upside: n/a
Dec 12, 2022
Reiterated: Buy
Price Target: $7
Current: $0.0001
Upside: n/a